submit news    HOME | FEEDBACK  


« NAVIGATION »
NEWS

- Bio/Medicine

- Chemicals

- Defense

- Drug Delivery

- Education

- Electronics

- Energy

- Events

- Grants

- Industry

- Investment

- Litigation

- Materials

- MEMS

- Nanofabrication

- Nanoparticles

- Nanotubes

- Optics

- Partnership

- Patent

- Products

- Quantum dots

- Research

- Smart Dust

- Software
COMPANIES
EVENTS

- Browse by Month

- Current Shows

- Previous Shows

- Submit Events
FEEDBACK
ADVERTISE
LINK TO US

« PARTNERS »
Become A Nanotechwire Partner

FEI Company

Veeco Instruments

Nano Science and Technology Institute

National Nanotechnology Initiative

Nanotechnology at Zyvex

Want to see your Company or Organization listed above? Become A Nanotechwire Partner Today - click here
« NEWSLETTER »



« SEARCH »







8/4/2008 5:30:56 PM
NanoViricides, Inc. Signs Rabies Agreement with CDC for Expanded Research

NanoViricides, Inc said that it has signed a Materials Cooperative Research and Development Agreement (MCRADA) with the United States Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia for rabies treatment study. The study, to be performed in collaboration with the CDC Rabies Program, is scheduled to begin soon.

"This study will expand on two successful animal studies of RabiCide-I performed previously by the government of Vietnam," said Eugene Seymour, MD, MPH, CEO of the Company, adding that "In those prior studies we achieved a 25% to 30% survival rate in animals that had already developed rabies. We believe this strong survival rate is a historical first achievement for any post-infection rabies treatment."

"Collaborating with CDC in designing and conducting these studies is an important step forward," said Anil R. Diwan, PhD, President of the Company, adding, "If the current studies are successful, we anticipate that this will be instrumental in helping our anti-rabies nanoviricide towards drug approval and widespread use across the world."

The Company has previously reported that Yale Research Professor Thomas Lentz, a leading expert in antiviral therapeutics based on virus-cell binding, has joined the Scientific Advisory Board. Prof. Lentz studied the binding of rabies virus to various cell receptors and has performed pioneering research in this field. The Company believes that it has put together a strong team to tackle rabies.

http://www.nanoviricides.com/

Other Headlines from NanoViricides ...
 - NanoViricides, Inc. President Invited on the NanoMedicine Panel at the NanoBusiness2010 Meeting in Chicago
 - NanoViricides Announces a Research Agreement With Leading Dengue Virus Researcher at the University of California, Berkeley
 - NanoViricides, Inc. to Present at the Nano and Green Tech 2009 Conference being held in conjunction with ChemShow 2009
 - NanoViricides Secures $4.3M in Financing
 - NanoViricides Platform Enables Rapid Development of Robust Nanomedicines Against Influenza and HIV

More Partnership Headlines ...
 - FUJIFILM Joins SEMATECH’s Resist Center for Advanced EUV Resist Development at UAlbany NanoCollege
 - Luna Innovations and Hansen Medical Expand Development Work
 - IBM and SARA Sign Collaboration Agreement on Petascale Computing
 - APIC Corporation and UAlbany NanoCollege launch $10M partnership to develop and commercialize innovative 'green' computer chip technology
 - Crocus Technology Strikes $300 Million Financing Deal with RUSNANO to Build Advanced MRAM Manufacturing Facility in Russia


« Back To List »

« GET LISTED »
- submit company
- submit news
- submit events
- advertise here

« EVENTS »
- More Events


Copyright © 2014 Nanotechwire.com | Privacy Policy |